Radiotherapy alone for nasal natural-killer/T-cell lymphoma [7]

Journal of Clinical Oncology

Volumn 24, Issue 17, 2006, Pages 2684-2685

  Bahl, Gaurav ^a   Laskar, Siddhartha ^a   Muckaden, Mary Ann ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; LETTER; MULTIMODALITY CANCER THERAPY; NATURAL KILLER T CELL; NOSE TUMOR; PRIORITY JOURNAL; RADIATION DOSE; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; NATURAL KILLER CELL; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; NOSE NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 33748133539     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.0889     Document Type: Letter

References (7)

1. Li YX, Yao B, Jin J, et al: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24:181-189, 2006
2. Cheung MM, Chan JK, Lau WH, et al: Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998
3. Liang R, Todd D, Chan TK, et al: Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 13:666-670, 1995
4. Ye YL, Zhou MH, Lu XY, et al: Nasopharyngeal and nasal malignant lymphoma: A clinicopathological study of 54 cases. Histopathology 20:511-516, 1992
5. Yamanaka N, Harabuchi Y, Sambe S, et al: Non-Hodgkin's lymphoma of Waldeyer's ring and nasal cavity: Clinical and immunological aspects. Cancer 56:768-776, 1985
6. Yamaguchi M, Kita K, Miwa H, et al: Frequent expression of P-glycoprotein/ MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-1256, 1995
7. Fukuda J, Yoshihara T, Arai Y, et al: Nasal NK-cell lymphoma [Japanese]. Rinsho Ketsueki 35:588-592, 1994